Conference
579 The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Sub-Analysis
Abstract
INTRODUCTION: Andexanet alfa is a recombinant modified human Factor Xa (FXa) decoy protein developed to reverse the anticoagulant effect of FXa inhibitors. METHODS: ANNEXA-4 was a prospective single-arm study of andexanet alfa in patients with acute major bleeding while taking a FXa inhibitor. Patients with major gastrointestinal (GI) bleeding were eligible if they had (1) signs/symptoms of hemodynamic compromise or (2) bleeding associated …
Authors
Siegal D; Beyer-Westendorf J; Yue P; Souza S; Nakamya J; Connolly SJ; Crowther M
Volume
114
Pagination
pp. s332-s333
Publisher
Wolters Kluwer
Publication Date
10 2019
DOI
10.14309/01.ajg.0000591848.50785.d5
Conference proceedings
The American Journal of Gastroenterology
Issue
1
ISSN
0002-9270